MAZE · Maze Therapeutics, Inc. · Documents
$32.58
+0.13 (+0.40%)
At close · Oct 21
Return incl. dividend (before tax)
Market Cap
$1.80B
Shares
55.55M
Volume · Oct 21
1.07M
Avg daily vol (3M)
634.4K
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| 8-K | Maze Therapeutics exchanged 2,776,007 shares of its common stock held by Frazier Life Sciences affiliates for pre-funded warrants to purchase an equivalent number of shares at $0.001 per share, leaving 53,931,889 shares outstanding as of October 16, 2026. | 2026-10-16 | 2026-10-15 | |
| Investor Event Transcript | — | 2026-09-09 | 2026-09-30 | |
| 8-K | — | 2026-08-17 | 2026-08-13 | |
| 8-K | — | 2026-08-11 | — | |
| 10-Q | — | 2026-08-11 | 2026-06-30 | |
| 8-K | — | 2026-06-10 | 2026-06-08 | |
| Investor Event Transcript | — | 2026-06-10 | 2026-06-30 | |
| Investor Event Transcript | — | 2026-06-03 | 2026-06-30 | |
| 8-K | — | 2026-05-22 | 2026-05-18 | |
| 10-Q | — | 2026-05-12 | 2026-03-31 | |
| 8-K | — | 2026-05-12 | — | |
| DEF 14A | — | 2026-04-28 | 2026-06-08 | |
| ARS | — | 2026-04-28 | 2025-12-31 | |
| DEFA14A | — | 2026-04-28 | — | |
| 8-K | — | 2026-04-22 | 2026-04-21 | |
| 10-K | — | 2026-03-25 | 2025-12-31 | |
| 8-K | — | 2026-03-25 | 2026-03-24 | |
| 8-K | — | 2026-02-04 | 2026-02-02 | |
| S-3ASR | — | 2026-02-04 | — | |
| 10-Q | — | 2025-11-06 | 2025-09-30 | |
| 8-K | — | 2025-11-06 | — | |
| S-1 | — | 2025-10-17 | — | |
| 8-K | — | 2025-10-06 | — | |
| 8-K | — | 2025-09-11 | 2025-09-10 | |
| 8-K | — | 2025-09-02 | — | |
| 8-K | — | 2025-08-12 | — | |
| 10-Q | — | 2025-08-12 | 2025-06-30 | |
| 8-K | — | 2025-05-14 | — | |
| 10-Q | — | 2025-05-14 | 2025-03-31 | |
| 10-K | — | 2025-03-31 | 2024-12-31 | |
| 8-K | — | 2025-03-31 | — | |
| S-1/A | — | 2025-01-30 | — | |
| S-1/A | — | 2025-01-27 | — | |
| S-1 | — | 2025-01-07 | — |
Showing 1–34 of 34 filings